Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Francesca Romana Mauro, Jacopo Olivieri et al.|Leukemia|2025Cited by 5
Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana LinfomiGian Matteo Rigolin, Antonio Cuneo, Antonio Urso et al.|Blood|2024Cited by 0
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive studyAndrea Visentin, Giuseppe Petruzzellis, Thomas Chatzikonstantinou et al.|Blood|2025Cited by 0